Pricing Log in Create free account

Lexeo Therapeutics, Inc. (LXEO) vs Sol-Gel Technologies Ltd. (SLGL)

Lexeo Therapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Lexeo Therapeutics, Inc. and Sol-Gel Technologies Ltd. are of similar size ($226.6M and $224.9M). Lexeo Therapeutics, Inc. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (−253.5% vs −6,630.2%). Across the 14 metrics below, Lexeo Therapeutics, Inc. leads on 7 and Sol-Gel Technologies Ltd. on 7.

Valuation

Metric LXEO SLGL Biotechnology median
P/E n/m n/m 8.50
P/S n/m 117.08 9.71
P/B 0.96 4.37 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 126.78 9.21
Earnings yield (43.56%) (8.78%) (33.15%)
Free cash flow yield (39.24%) (10.12%) (25.50%)

Profitability

Metric LXEO SLGL Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (46.76%) (40.85%) (56.36%)
Return on assets (40.50%) (35.11%) (48.04%)
Return on invested capital (253.48%) (6,630.24%) 0.00%

Growth

Metric LXEO SLGL Biotechnology median
Revenue growth (TTM) — (92.50%) 6.02%
EPS growth (last fiscal year) 39.81% 42.37% 30.26%
Revenue growth, 5-year CAGR — 17.19% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LXEO SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.89 10.37 4.72
Net debt to EBITDA 1.67 3.23 0.96

Dividend

Metric LXEO SLGL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LXEO SLGL Biotechnology median
Market cap 226.56m 224.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack